Bram H Goldstein (Mark A Rettenmaier)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Placebo Controlled

Metastatic Breast Cancer

Top Venues

Journal of gynecologic oncology

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Archives of gynecology and obstetrics

The journal of obstetrics and gynaecology research

This page only lists publications with an associated author ORCID identifier.

Publications

John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 30 (3) (2024)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 30 (3) (2024)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
Medical marijuana in the treatment of cancer-associated symptoms. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
John P Micha, Bram H Goldstein, Randy D Bohart, Bram H Goldstein
Reply to the letter to the editor: a response to Tran and Egilman. Archives of gynecology and obstetrics (2023)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
Prolonged endocrine therapy in the management of hormone receptor-positive early-stage breast cancer: What is the appropriate duration? The journal of obstetrics and gynaecology research (2023)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology 34 (2) (2022)
John P Micha, Mark A Rettenmaier, Randy D Bohart, Bram H Goldstein
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. Journal of gynecologic oncology (2022)